Coagulation Factor X Human
drugOn this page
Also known as CoagadexCoagulation factor xhumanFactor xHuman coagulation factor xHuman factor x
Summary
Coagulation Factor X Human (CHEMBL4297951) is an approved unknown (ATC B02BD13); indicated across 3 conditions including factor x deficiency and coagulation protein disease.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Unknown
- ATC class: B02BD13
- Indications: 3 conditions
- Clinical trials: 4
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL4297951 |
| Name | Coagulation Factor X Human |
| Type | Unknown |
| Max phase | 4 |
| ATC | B02BD13 |
Also known as: Coagadex, Coagulation factor x, Coagulation factor x human, human, Factor x, Human coagulation factor x, Human factor x, COAGULATION FACTOR X HUMAN
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
3 indications (3 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| factor X deficiency | 4 | MONDO:0002247 | MONDO:0002247 |
| coagulation protein disease | 4 | MONDO:0002242 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 4.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE3 | 3 |
| Not specified | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00930176 | PHASE3 | COMPLETED | A Study Investigating Treatment Factor X in People With Factor X Deficiency |
| NCT01086852 | PHASE3 | TERMINATED | Safety & Efficacy of BPL’s High Purity FACTOR X in Treatment of Factor X Deficient Subjects Undergoing Surgery |
| NCT01721681 | PHASE3 | COMPLETED | A Study to Investigate Bio Product Laboratory Ltd (BPL’s) Factor X in the Prophylaxis of Bleeding in Children <12 Years |
| NCT03161626 | Not specified | COMPLETED | Registry Study of COAGADEX® Patients With Moderate or Severe Hereditary Factor X Deficiency Undergoing Major Surgery |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: factor X deficiency, coagulation protein disease